Provision of free alemtuzumab (anti-CD52) to patients with chronic lymphocytic leukemia refractory to conventional chemotherapy
Dr Leung, Anskar Yu Hung (Principal investigator)
Professor Kwong Yok Lam (Co-Investigator)
anti-CD52, leukemia, chemotherapy, alemtuzumab
Others - Medicine, Dentistry and Health
HKU Project Code
S.K. Yee Medical Foundation - General Award
To provide free alemtuzumab for the treatment of refractory CLL to patients cannot afford this drug; to impove microbiological surveillance against fungal infection among patients who receive this drug.